aTyr Pharma FY2025 EPS Estimate Raised by Cantor Fitzgerald

Key Points

• Cantor Fitzgerald has revised its FY2025 earnings per share (EPS) estimate for aTyr Pharma to ($0.64), an improvement from the previous estimate of ($0.66), while maintaining a "Neutral" rating on the stock.
• Several research firms have downgraded aTyr Pharma, with Jones Trading and HC Wainwright both reducing ratings to "hold" as of Monday, and Wall Street Zen downgrading to "sell" earlier in August.
• The stock opened at $1.03 on Thursday, with a market capitalization of approximately $100.44 million, while institutional investors own about 61.72% of the company’s shares.

aTyr Pharma, Inc. (NASDAQ:ATYR - Free Report) - Research analysts at Cantor Fitzgerald upped their FY2025 earnings per share (EPS) estimates for shares of aTyr Pharma in a report issued on Tuesday, September 16th. Cantor Fitzgerald analyst P. Agrawal now expects that the company will post earnings of ($0.64) per share for the year, up from their previous estimate of ($0.66). Cantor Fitzgerald currently has a "Neutral" rating on the stock. The consensus estimate for aTyr Pharma's current full-year earnings is ($0.91) per share. Cantor Fitzgerald also issued estimates for aTyr Pharma's FY2026 earnings at ($0.39) EPS.

ATYR has been the topic of a number of other reports. Wall Street Zen cut aTyr Pharma from a "hold" rating to a "sell" rating in a research report on Saturday, August 9th. Leerink Partners reiterated a "market perform" rating on shares of aTyr Pharma in a research report on Monday, September 15th. Leerink Partnrs lowered aTyr Pharma from a "strong-buy" rating to a "hold" rating in a research note on Monday, September 15th. HC Wainwright cut aTyr Pharma from a "buy" rating to a "neutral" rating in a report on Monday, September 15th. Finally, Jones Trading lowered aTyr Pharma from a "strong-buy" rating to a "hold" rating in a research report on Monday, September 15th. One investment analyst has rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $23.25.

aTyr Pharma Stock Performance

Shares of NASDAQ ATYR traded up $0.06 during trading hours on Thursday, reaching $1.05. The stock had a trading volume of 21,242,394 shares, compared to its average volume of 17,474,092. The business's fifty day moving average is $4.85 and its two-hundred day moving average is $4.29. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.63 and a quick ratio of 5.63. The company has a market cap of $102.89 million, a price-to-earnings ratio of -1.31 and a beta of 1.01. aTyr Pharma has a twelve month low of $0.95 and a twelve month high of $7.29.

aTyr Pharma (NASDAQ:ATYR - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.04).

Institutional Investors Weigh In On aTyr Pharma

Several large investors have recently added to or reduced their stakes in the business. Oxford Asset Management LLP acquired a new stake in aTyr Pharma in the second quarter valued at approximately $70,000. Octagon Capital Advisors LP lifted its holdings in aTyr Pharma by 7.5% during the second quarter. Octagon Capital Advisors LP now owns 3,820,000 shares of the company's stock worth $19,367,000 after acquiring an additional 268,000 shares during the period. BNP Paribas Financial Markets bought a new stake in shares of aTyr Pharma in the second quarter valued at $99,000. California State Teachers Retirement System bought a new stake in shares of aTyr Pharma in the second quarter valued at $28,000. Finally, Raymond James Financial Inc. raised its stake in shares of aTyr Pharma by 79.3% in the second quarter. Raymond James Financial Inc. now owns 24,839 shares of the company's stock valued at $126,000 after buying an additional 10,989 shares during the period. Institutional investors and hedge funds own 61.72% of the company's stock.

aTyr Pharma Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.